Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Objective: To eradicate hepatitis C virus (HCV) infection among prisoners using specific models of screening and linkage to care.

Patients And Methods: The Sicilian Network for Therapy, Epidemiology and Screening in Hepatology (SINTESI) runs an HCV point-of-care project in all 23 prisons in Sicily. All prisoners received information on HCV screening and the possibility of receiving treatment with direct-acting antiviral (DAA) therapy during imprisonment. HCV status was assessed by rapid oral test and immediate reflex testing for HCV-RNA by Xpert HCV Viral Load. HCV-RNA-positive subjects received DAA therapy within 72 hours of screening.

Results: The project was conducted from October 18, 2021, through March 24, 2023. Among 5912 prisoners (98% of the entire prison population) informed of the screening project, 5050 (85.4%) accepted HCV testing. The mean age was 41.8 years (range, 18-86 years), and 4843 (95.9%) were males. Overall, 245 subjects (4.8%) tested positive for anti-HCV. Among 245 anti-HCV-positive prisoners, 20 (8.1%) refused the HCV-RNA test; 100 (40.9%) tested negative (80 had a previous DAA treatment) and 125 (51.1%) tested positive for HCV-RNA. Twelve (4.9%) of the latter refused treatment, whereas 113 (46.2%) started a cycle of DAA drugs during imprisonment. Of these, 99 (87.9%) completed DAA therapy, and 98 (86.7%) obtained HCV clearance.

Conclusion: The findings highlight the importance of tailored interventions for high-risk populations, and the model is replicable in other regions and contexts.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12302490PMC
http://dx.doi.org/10.1016/j.mayocpiqo.2025.100643DOI Listing

Publication Analysis

Top Keywords

daa therapy
12
hepatitis virus
8
tested positive
8
hcv
7
daa
5
point-of-care testing
4
treatment
4
testing treatment
4
treatment hepatitis
4
virus prisons
4

Similar Publications

Objective: Hepatocellular carcinoma (HCC) can still occur in patients with chronic hepatitis C after achieving a sustained virologic response (SVR) with direct-acting antiviral (DAA) therapy. Therefore, we aimed to identify and validate predictors and HCC risk models using longitudinal data.

Method: This retrospective cohort study included patients who achieved SVR after DAA therapy.

View Article and Find Full Text PDF

Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype-specific to pan-genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines. This study examined trends in DAA dispensing in light of evolving treatment regimens.

View Article and Find Full Text PDF

Normalization of serum alpha fetoprotein after direct acting antivirals in hepatitis C patients lowers hepatocellular carcinoma risk.

Sci Rep

September 2025

Division of Gastroenterology and Hepatology, Department of Internal Medicine, Far Eastern Memorial Hospital, No. 21, Nanya South Road, Section 2, Banqiao District, New Taipei City, 220216, Taiwan.

The elevation of serum alpha-fetoprotein (AFP) is frequently observed in patients with chronic hepatitis C (CHC). In most cases, the level decreased after antiviral treatment. This study investigated the relationship between post-treatment AFP normalization and the risk of hepatocellular carcinoma (HCC) in CHC patients without baseline HCC.

View Article and Find Full Text PDF

Background: People with human immunodeficiency virus (HIV; PWH) are at increased risk of hepatitis C virus (HCV) coinfection and experiencing negative clinical outcomes. We evaluated direct-acting antiviral (DAA) initiation among PWH with HCV to identify factors associated with initiation.

Methods: US and Canadian PWH ≥18 years with a detectable HCV RNA in the North American AIDS Cohort Collaboration on Research and Design were followed up from the latest of first detectable HCV viremia, antiretroviral therapy initiation, enrollment date, or 1 January 2014 until the first of DAA prescription, clearance of HCV viremia, loss to follow-up, death, or 31 December 2021.

View Article and Find Full Text PDF

Purpose: Hirschsprung's disease (HSCR) is an intestinal disorder characterized by the absence of nerve cells in parts of the intestinal tract. The definitive diagnosis is confirmed by a full-thickness rectal biopsy to verify the absence of ganglion cells. However, incomplete removal often causes post-operative complications.

View Article and Find Full Text PDF